Ablynx enters into research and license agreement with Wyeth
Ablynx, has announced that they have entered into an exclusive research collaboration and license agreement with Wyeth Pharmaceuticals, a division of Wyeth, to discover, develop and commercialise Nanobodies® directed at the tumour necrosis factor alpha (TNF-) protein and its receptors that target diseases in multiple therapeutic areas.
Ablynx has granted Wyeth exclusive worldwide rights to Nanobodies® targeting the clinically validated target TNF-. Ablynx and Wyeth will collaborate to advance these novel biologics through preclinical development. Ablynx will receive an initial payment, research support and milestone payments. Potential payments to Ablynx could total up to $212.5 million for the successful development and commercialisation of multiple products. In addition Ablynx will receive royalties on product sales.
Topics
Organizations
Other news from the department business & finance
![Newsletter](https://img.chemie.de/assets/bionity/images/newsletter.png)
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.